Search Results - "Propper, D J"

Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C by PROPPER, D. J, MCDONALD, A. C, KAYE, S. B, GANESAN, T. S, TALBOT, D. C, HARRIS, A. L, TWELVES, C, MAN, A, THAVASU, P, BALKWILL, F, BRAYBROOKE, J. P, CAPONIGRO, F, GRAF, P, DUTREIX, C, BLACKIE, R

“…N-Benzoyl staurosporine (PKC412) is a protein kinase C inhibitor with antitumor activity in laboratory models. We determined the toxicity of oral PKC412…”
Get full text

Neuroendocrine tumours of the gallbladder: three cases and a review of the literature by Iype, S, Mirza, T A, Propper, D J, Bhattacharya, S, Feakins, R M, Kocher, H M

“…Primary neuroendocrine tumours (NETs) of the gallbladder are rare. In the absence of any randomised controlled trials or prospective case series, we sought…”
Get full text

A phase II study of bryostatin 1 in metastatic malignant melanoma by PROPPER, D. J, MACAULAY, V, O'BYRNE, K. J, BRAYBROOKE, J. P, WILNER, S. M, GANESAN, T. S, TALBOT, D. C, HARRIS, A. L

“…Bryostatin 1 is a protein kinase C partial agonist which has both antineoplastic and immune-stimulatory properties, including the induction of cytokine release…”
Get full text

Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer by LEVITT, N. C, PROPPER, D. J, GANESAN, T. S, MADHUSUDAN, S, BRAYBROOKE, J. P, ECHETA, C, TE POELE, R, DAVIES, S. L, FLANAGAN, E, HICKSON, I. D, JOEL, S

“…A pharmacokinetically guided phase I study of topotecan and etoposide phosphate was conducted in recurrent ovarian cancer. The scheduling of the topoisomerase…”
Get full text

Phase I trial of the selective mitochondrial toxin MKT 077 in chemo-resistant solid tumours by Propper, D. J., Braybrooke, J. P., Taylor, D. J., Lodi, R., Styles, P., Cramer, J. A., Collins, W. C. J., Levitt, N. C., Talbot, D. C., Ganesan, T. S., Harris, A. L.

“…Background: MKT 077 is a rhodacyanine dye analogue which preferentially accumulates in tumour cell mitochondria. It is cytotoxic to a range of tumours. In this…”
Get full text

Use of Positron Emission Tomography in Pharmacokinetic Studies to Investigate Therapeutic Advantage in a Phase I Study of 120-Hour Intravenous Infusion XR5000 by Propper, D J, de Bono, J, Saleem, A, Ellard, S, Flanagan, E, Paul, J, Ganesan, T S, Talbot, D C, Aboagye, E O, Price, P, Harris, A L, Twelves, C

“…XR5000 (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide) is a topoisomerase I and II inhibitor. Because the cytotoxicity of XR5000 increases markedly with…”
Get full text

Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer by O'BYRNE, K. J, DOBBS, N, PROPPER, D. J, BRAYBROOKE, J. P, KOUKOURAKIS, M. I, MITCHELL, K, WOODHULL, J, TALBOT, D. C, SCHALLY, A. V, HARRIS, A. L

“…RC-160 (octastatin/vapreotide) is a potent octapeptide analogue of somatostatin with growth inhibitory activity in experimental tumours in vitro and in vivo,…”
Get full text

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine by PROPPER, D. J, BRAYBROOKE, J. P, LEVITT, N. C, O'BYRNE, K, CHRISTODOULOS, K, HAN, C, TALBOT, D. C, GANESAN, T. S, HARRIS, A. L

“…This study assessed response rates to combination dacarbazine (DTIC), BCNU (carmustine), cisplatin and tamoxifen (DBPT) chemotherapy in patients with…”
Get full text

Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha by BRAYBROOKE, J. P, PROPPER, D. J, TALBOT, D. C, HARRIS, A. L, O'BYRNE, K. J, KOUKOURAKIS, M. I, PATTERSON, A. V, HOULBROOK, S, LOVE, S. D, VARCOE, S, TAYLOR, M, GANESAN, T. S

“…Thymidine phosphorylase (TP) is an essential enzyme for the biochemical activation of 5-fluorouracil (5-FU). Interferon upregulates TP in vivo, although the…”
Get full text

Phase I Study of the Novel Cyclic AMP (cAMP) Analogue 8-Chloro-cAMP in Patients with Cancer: Toxicity, Hormonal, and Immunological Effects by PROPPER, D. J, SAUNDERS, M. P, HARRIS, A. L, SALISBURY, A. J, LONG, L, O'BYRNE, K. J, BRAYBROOKE, J. P, DOWSETT, M, TAYLOR, M, TALBOT, D. C, GANESAN, T. S

“…The cyclic AMP (cAMP)-dependent protein kinase regulatory subunit RI is overexpressed in cancer cells. 8-Chloro-cAMP (8-Cl-cAMP) is an RII site-specific…”
Get full text

Acute transverse myelopathy complicating systemic lupus erythematosus by Propper, D J, Bucknall, R C

“…A sixteen year old girl with systemic lupus erythematosus developed acute transverse myelopathy. She was treated with high dose steroids, cyclophosphamide, and…”
Get full text

Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer by PROPPER, D. J, LEVITT, N. C, HARRIS, A. L, O'BYRNE, K, BRAYBROOKE, J. P, TALBOT, D. C, GANESAN, T. S, THOMPSON, C. H, RAJAGOPALAN, B, LITTLEWOOD, T. J, DIXON, R. M

“…BW12C (5-[2-formyl-3-hydroxypenoxyl] pentanoic acid) stabilizes oxyhaemoglobin, causing a reversible left-shift of the oxygen saturation curve (OSC) and tissue…”
Get full text

A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma by O'Byrne, K. J., Philip, P. A., Propper, D. J., Braybrooke, I. P., Saunders, M. P., Bates, N. P., Taylor, M. A., Madigan, D., Ganesan, T. S., Talbot, D. C., Harris, A. L.

“…Background: Hydroxyurea (HU), an inhibitor of ribonucleotide reductase, may potentiate the activity of 5-fiuorouracil (5-FU) and folinic acid (FA) by reducing…”
Get full text

Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen by BRAYBROOKE, J. P, HOULBROOK, S, CRAWLEY, J. E, PROPPER, D. J, O'BYRNE, K. J, STRATFORD, I. J, HARRIS, A. L, SHUKER, D. E. G, TALBOT, D. C

“…To develop, using dacarbazine as a model, reliable techniques for measuring DNA damage and repair as pharmacodynamic endpoints for patients receiving…”
Get full text

A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract by Braybrooke, J. P., O'Byrne, K. J., Saunders, M. P., Propper, D. J., Salisbury, A. J., Boardman, P., Taylor, M., Ganesan, T. S., Talbot, D. C., Harris, A. L.

“…Background: Mitomycin C and etoposide have both demonstrated activity against gastric carcinoma. Etoposide is a topoisomerase II inhibitor with evidence for…”
Get full text

Phase I and Pharmacological Study of the Oral Matrix Metalloproteinase Inhibitor, MMI270 (CGS27023A), in Patients with Advanced Solid Cancer by LEVITT, Nicola C, ESKENS, Ferry A. L. M, NAKAJIMA, Motowo, TALBOT, Denis C, STEWARD, William P, HARRIS, Adrian L, VERWEIJ, Jaap, O'BYRNE, Ken J, PROPPER, David J, DENIS, Louis J, OWEN, Samantha J, CHOI, Les, FOEKENS, John A, WILNER, Sue, WOOD, Jeanette M

“…This Phase I study of MMI270, an p.o. administered matrix metalloproteinase inhibitor, assessed toxicity, pharmacokinetics, and tumor response data and…”
Get full text

Breast vasculitis in association with breast gigantism in a pregnant patient with systemic lupus erythematosus by Propper, D J, Reid, D M, Stankler, L, Eastmond, C J

“…A 24 year old woman with systemic lupus erythematosus (SLE) developed widespread necrotic skin ulceration and gigantism of both breasts during an exacerbation…”
Get full text

Antigen presentation and HLA-DR expression by FK-506-treated human monocytes by WOO, J, PROPPER, D. J, THOMSON, A. W

“…The novel macrolide immunosuppressant FK-506 demonstrated superior potency to cyclosporin A (CsA) in the inhibition of purified protein derivative…”
Get full text

Glomerulotubular function in long-term renal allograft recipients. A comparison of conventional therapy with cyclosporine by Propper, D J, Whiting, P H, Mackay, J, Catto, G R

“…Glomerular and tubular function were assessed, using a lithium clearance technique, in two groups of renal allograft recipients at least one year after…”
Get more information

Immune responses to noninherited maternal RT1A antigens in inbred rats by Propper, D J, Woo, J, Stewart, K N, Catto, G R, Power, D A

“…Humoral responses to non-inherited maternal class I antigens (class I NIMAs) were assessed in 3 groups of inbred rats expressing the RT1u phenotype. Group 1…”
Get more information